Chemomab Therapeutics Ltd (CMMB) Actualités

Chemomab Therapeutics to Report Third Quarter 2024 Financial Results and Provide a Business Update

TEL AVIV, Israel, Oct. 30, 2024 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (“Chemomab” or...

Chemomab Therapeutics Announces Late-Breaking Oral Presentation of CM-101 Phase 2 Results in Primary Sclerosing Cholangitis at AASLD The Liver Meeting® 2024

TEL AVIV, Israel, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (Chemomab), a...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Chemomab Therapeutics to Present at October 2024 Investor Conferences

TEL AVIV, Israel, Oct. 01, 2024 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (Chemomab), a...

Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]

Form 144 - Report of proposed sale of securities

Form 424B3 - Prospectus [Rule 424(b)(3)]

Form EFFECT - Notice of Effectiveness

Chemomab Therapeutics to Present at September 2024 Investor Conferences

TEL AVIV, Israel, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (Chemomab), a...

Form F-3 - Registration statement by foreign private issuers

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Chemomab Therapeutics Announces Second Quarter 2024 Financial Results and Provides Corporate Update

──Reported Positive Phase 2 Results Demonstrating Safety and Anti-Fibrotic, Anti-Inflammatory and...

Chemomab Therapeutics to Report Second Quarter 2024 Financial Results and Provide a Business Update

TEL AVIV, Israel, Aug. 12, 2024 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (“Chemomab” or...

Form D - Notice of Exempt Offering of Securities

Chemomab Therapeutics Announces Closing of $10 Million Private Placement

— HBM Healthcare Investments, OrbiMed and Sphera Biotech Master Fund LP Participated in the Financing that...